Conditions: Post Menopausal Osteoporosis
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 41
Healthy volunteers: no

Brief summary:
This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with post-menopausal osteoporosis. Patients will receive Bonviva/Boniva at a dose of 3 mg intravenously every three months. Anticipated time on study treatment is 12 months with a follow-up of 12 months.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: ibandronate [Bonviva/Boniva]
Intervention descriptions: intervention 1: 3 mg intravenously every 3 months

Protocol document: